TECH
Healthcare · Biotechnology
Performance
TECH (TECH) Stock Analysis 2026
Rule-based · Updated daily · Not financial advice
TECH (TECH) operates in the Biotechnology space within the Healthcare sector. With a market cap of $8.8B, it qualifies as a small-cap company. Revenue has been contracting year-over-year, a headwind that investors will watch closely in upcoming earnings.
- Forward P/E (27.2×) is lower than trailing P/E (79.9×) — analysts expect earnings to improve
- Earnings grew 129% YoY — bottom-line is expanding fast
- Current ratio of 4.5× — ample short-term liquidity
- High P/E of 79.9× implies high expectations already priced in — leaves little room for disappointment
- Revenue declined 2% YoY — warning sign for business momentum
- High debt-to-equity of 13.92× increases financial risk, especially with elevated interest rates
Verdict
Hold
Mixed signals — strengths and risks roughly balance. Wait for a clearer catalyst.
AI Insight
Powered by ClaudeAI-generated analysis for informational purposes only. Not financial advice.
Related Articles
Revenue & Results
Dividends
Current DY
0.57%
5Y Avg Annual
$0.2880
Last Payment
$0.0800
Ex-Date
05/18/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest05/18/2026 | 05/29/2026 | $0.0800 | 0.57% |
02/13/2026 | 02/24/2026 | $0.0800 | 0.57% |
11/17/2025 | 11/28/2025 | $0.0800 | 0.57% |
08/18/2025 | 08/29/2025 | $0.0800 | 0.57% |
05/19/2025 | 05/30/2025 | $0.0800 | 0.57% |
02/14/2025 | 02/25/2025 | $0.0800 | 0.57% |
11/08/2024 | 11/19/2024 | $0.0800 | 0.57% |
08/19/2024 | 08/30/2024 | $0.0800 | 0.57% |
Magic Number
Shares needed to self-fund your next purchase
$55.95
Price
$0.0800
Last div. (quarterly)
700
shares
Own 700 TECH shares ($39,161.50) and each quarterly dividend pays for 1 new share — the snowball runs on its own.
Investment target
$39,161.50
New shares / year
+4 shares
If You Had Invested…
Hypothetical return based on historical prices
* Dividend reinvestment calculated at ex-date price. For informational purposes only.
Earnings
Next Earnings
Aug 5, 2026
50
days
EPS (TTM)
$0.70
P/E (TTM)
79.9
Fwd P/E
27.2
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Key Statistics
Valuation
Trading
Dividends
Profitability
Balance Sheet
Fair Value Estimates
Current price: $55.95
Graham Number
√(22.5 × EPS × Book Value)
$14.25
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$5.33
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
7/10
70% score
Pays dividends
15Y hist.15+ years of dividend history
Dividend consistency (5Y+)
15 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
5.3%Return on equity — measures how efficiently capital is used
Positive profit margin
9.0%Net profit margin must be positive — company earns more than it spends
Revenue growth (annual)
-1.5%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
+128.6%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
13.92×Low financial leverage reduces risk of distress
Current ratio above 1
4.49×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$149M/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
0.57%Stock must distribute income to shareholders
Related Assets
Healthcare
About TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Sector
Healthcare
Industry
Biotechnology
Location
Minneapolis, United States
Employees
3,100